Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Multivitamin may shield ozempic users from hidden nutrient shortages

NCT ID NCT06981936

Disease control Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 3 times

Summary

This study tests whether a daily multivitamin tablet can prevent vitamin and mineral deficiencies in people using GLP-1 drugs (like Ozempic or Saxenda) for weight loss. These drugs suppress appetite, which can lead to low nutrient intake. The trial will compare a multivitamin to a placebo over 12 months in 150 adults with obesity. Researchers will measure blood nutrient levels to see if the supplement helps maintain healthy levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Balance Tablet (multivitamin and mineral supplement)
What this could lead to
If it works, this could show that taking a daily multivitamin helps prevent nutrient deficiencies in people using GLP-1 drugs for weight loss.
What could go wrong
This is a relatively small, early-phase trial. The supplement may not prevent all deficiencies, and results may not apply to everyone. There is little risk from the supplement itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

150 people

The number who actually took part.

Started

May 2025

Finished

May 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Adults aged 18-65 years. * BMI ≥ 30 kg/m² (obesity), or BMI ≥ 27 kg/m² with at least one obesity-related comorbidity (e.g., type 2 diabetes, hypertension). * Currently using a GLP-1 receptor agonist medication for weight management (e.g., semaglutide or liraglutide) and planning to continue it for the next year as part of their weight loss regimen. Exclusion Criteria: * • Any pre-existing condition that affects nutrient absorption or metabolism (e.g., malabsorptive gastrointestinal disorders such as celiac disease or inflammatory bowel disease, prior bariatric surgery). * Use of other weight loss medications (besides the GLP-1 RA) or use of high-dose vitamin/mineral supplements or other nutritional supplements that could influence vitamin/mineral status. * Pregnancy or lactation (women of childbearing potential will undergo a pregnancy test and must agree to use contraception during the study). * Known hypersensitivity or allergy to components of the Balance multivitamin formulation. * Significant chronic illnesses (e.g., end-stage renal disease, advanced liver disease) that in the investigator's judgment would interfere with participation or outcomes of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Micronutrient deficiencies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder Weight Loss nutritional deficiency disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Micronutrient deficiencies

Contacts and locations

Locations

  • Facility Name: The surgical department of Medical Research Institute Hospital, Alexandria University, Alexandria, Facility

    Alexandria, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.